Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Heatmap
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
RCUS
#1722
Arcus Biosciences, Inc.
22.9
3
USD
+2.46%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
+2.46%
Changement Mensuel
+1.69%
Evolution sur 6 mois
+46.14%
Changement Annuel
+202.51%
Clôture Précédente
22.3
8
Open
22.9
3
Bid
Ask
Low
22.8
3
High
23.0
9
Volume
283
Marchés
Actions des Marchés US
Soins de Santé
RCUS
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
70.88 M
71.06 M
73.01 M
90.86 M
105.84 M
125.35 M
—
Valuation ratios
Enterprise value
1.67 B
2.73 B
1.27 B
1.66 B
1.58 B
2.96 B
5.73 B
Price to earnings ratio
-11.58
57
-5.44
-4.74
-4.74
-7.24
-15.54
Price to sales ratio
18.35
7.82
12.99
12.45
5.2
10.36
24.5
Price to cash flow ratio
12.79
-11.69
3.32
-4.76
-7.89
-5.31
-13.1
Price to book ratio
2.83
3.56
2.21
3.15
2.77
4.06
5.43
Enterprise value to EBITDA ratio
-13.41
46.22
—
-4.63
-4.02
-6.93
-13.2
Profitability ratios
Return on assets %
-0.16
0.03
-0.2
-0.28
-0.25
-0.31
-0.33
Return on equity %
-0.24
0.06
-0.41
-0.66
-0.58
-0.56
-0.69
Return on invested capital %
-102.44
25.71
-151.5
-333.84
-370.54
-517.25
—
Gross margin %
100
100
100
100
100
100
400
Operating margin %
-160.27
14.17
-250
-290.6
-127.91
-156.28
-1 332.32
EBITDA margin %
-160.33
15.41
—
-306.84
-137.6
-161.54
-1 369.11
Net margin %
-158.49
13.8
-238.39
-262.39
-109.69
-142.91
-1 240.44
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
6.05
7.6
5.53
4.52
4.5
4.36
17.88
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.16
0.32
0.08
0.1
0.23
0.22
0.22
Solvency ratios
Debt to assets ratio
—
—
—
—
0.14
0.17
0.44
Debt to equity ratio
—
—
—
—
0.33
0.31
0.88
Long term debt to total assets ratio
—
—
—
—
0.04
0.09
0.32
Long term debt to total equity ratio
—
—
—
—
0.1
0.16
0.65
Per share metrics
Operating cash flow per share
2.03
-3.46
6.08
-4.14
-1.89
-4.49
-4.62
EBIT per share
-2.27
0.73
-3.89
-4.59
-3.66
-3.59
-3.71
EBITDA per share
-2.27
0.8
—
-4.85
-3.94
-3.72
-3.83
Total debt per share
—
—
—
—
1.76
1.84
4.52
Cash per share
3.17
6.75
14.01
10.26
10.85
9.13
35.62
Net current asset value per share
13.43
17.06
14.82
11.23
11.28
9.38
36.78
Tangible book value per share
9.17
11.38
9.13
6.24
5.38
5.88
20.52
Working capital per share
11.21
14.81
12.14
8.74
8.77
7.23
28.5
Book value per share
9.17
11.38
9.13
6.24
5.38
5.88
20.52
Nouvelles
La directrice des opérations d’Arcus Biosciences, Jennifer Jarrett, démissionnera le 30 mars
Arcus Biosciences à la conférence Leerink : données prometteuses du casdatifan
Arcus Biosciences at Leerink Conference: Casdatifan’s Promising Data
Arcus Biosciences: Q4 Beat And Casdatifan’s Story So Far (NYSE:RCUS)
Palantir, United Tech among market cap stock movers on Monday
Palantir and AeroVironment among market cap stock movers on Monday
Arcus Biosciences, Inc. 2025 Q4 - Results - Earnings Call Presentation (NYSE:RCUS) 2026-02-27
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change
Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues